Protein Production
293FT, 293E, CHO

Truly Functional Protein
95% Purity
1-10 mg in 2 weeks

GeneExpressoMax™
293Expresso™

Transfection Reagents
* 90% Efficiency
* 95% Viability
* No sera interference
* Simple protocol
* High-throughput
* Only $98/ml

Baculovirus
Functional Protein
95% Purity
Fast turnaround
1-10 mg from Sf9 cells

Adenovirus, AAV
& Lentivirus

ORF or shRNA
* High Titer
* Cre, FLP, ΦC31
* Protein Kinases
* Transcription Factors
* Luciferases, GFP, RFP
* Protein Production
* Stable Cell Line


Excellgen

KU CENTER FOR NEUROPROTECTION IN PARKINSON´S DISEASE

Rajesh Pahwa
University Of Kansas Medical Center, Msn 1039, Kansas City, Ks 66160

Grant 3U10NS044469-09S1 from National Institute Of Neurological Disorders And Stroke

Abstract: The University of Kansas has all of the necessary components to become a Parkinson´s Disease Neuroprotection Clinical Trial Center. The University of Kansas is an established Clinical Trials Center with the necessary space to efficiently conduct clinical trials, prepare and process lab specimens and securely and confidentially maintain study medication and documentation. An experienced clinical trial team is currently in place to assure that the studies are conducted in a manner that allows for accurate, efficient and timely collection of data and provides a safe and pleasant environment for the patients. The Clinical Trial Staff have all received training and certification to conduct clinical trials from the University of Kansas Research Compliance Office and have been trained and currently follow Good Clinical Practice Guidelines to assure the safety and protection of study participants. The Principle Investigator, Dr. Rajesh Pahwa, has extensive experience in developing, conducting and monitoring clinical trials and an excellent track record in the recruitment of patients. The Center currently works closely with the Parkinson Association of Greater Kansas City, and all of its support groups to facilitate patient recruitment. The University of Kansas Parkinson´s Disease Center is willing and dedicated to adhere to a common protocol and to cooperate with other centers and NINDS in the conduct of both pilot studies and the main efficacy study

Keywords: Certification; Cities; Clinical Practice Guideline; Clinical Practice Guidelines; Clinical Trials; Clinical Trials, Unspecified; Conduct Clinical Trials; Confidentiality; Data; Data Collection; Disease; Disorder; Documentation; Double-Blind Method; Double-Blind Study; Double-Blinded; Double-Masked Method; Double-Masked Study; Drugs; Ensure; Environment; Good Clinical Practice; Idiopathic Parkinson Disease; Investigators; Kansas; Lewy Body Parkinson Disease; Medication; Monitoring Clinical Trials; NIH; National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Institutes of Health (U.S.); Paralysis Agitans; Parkinson; Parkinson Disease; Parkinson`s; Parkinson`s disease; Parkinsons disease; Participant; Patient Recruitments; Patients; Performance; Pharmaceutic Preparations; Pharmaceutical Preparations; Pilot Projects; Primary Parkinsonism; Process; Protocol; Protocols documentation; Randomized Clinical Trials; Recruitment Activity; Research; Research Personnel; Research Specimen; Researchers; Safety; Self-Help Groups; Specimen; Support Groups; Training; United States National Institutes of Health; Universities; Work; clinical investigation; disease/disorder; drug/agent; experience; neuroprotection; pilot study; privacy of information; recruit; self help organization

Project start date: 2006-01-20

Project end date: 2012-11-30

Budget start date: 1-DEC-2009

Budget end date: 30-NOV-2010

PFA/PA: RFA-NS-02-010

3U10NS044469-09S1 (2010): $42600


Sponsored Links Excellgen http://Excellgen.com

Recombinant Lentivirus & Adenovirus
High Yield and High Titer up to 1010 (lentivirus) and 1013 (adenovirus) for Guaranteed Expression of GOI. $3000, $2500
Transient Protein Expression in CHO and HEK293 Cells
Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. $5500, $3950
Baculovirus Protein Expression
Fast turn around, >95% purity functional protein. No outsourcing to China or India. $5500, $3950


Grants awarded to Rajesh Pahwa

KU Center For Neuroprotection In Parkinson s Disease

Rajesh Pahwa, Professor Of Neurology
University Of Kansas Medical Center Msn 1039 Kansas City, Ks 66160

Grant 5U10NS044469-06 from National Institute Of Neurological Disorders And Stroke IRG: ZNS1

Abstract: The University of Kansas has all of the necessary components to become a Parkinson s Disease Neuroprotection Clinical Trial Center. The University of Kansas is an established Clinical Trials Center with the necessary space to efficiently conduct clinical trials, prepare and process lab specimens and securely and confidentially maintain study medication and documentation. An experienced clinical trial team is currently in place to assure that the studies are conducted in a manner that allows for accurate, efficient and timely collection of data and provides a safe and pleasant environment for the patients. The Clinical Trial Staff have all received training and certification to conduct clinical trials from the University of Kansas Research Compliance Office and have been trained and currently follow Good Clinical Practice Guidelines to assure the safety and protection of study participants. The Principle Investigator, Dr. Rajesh Pahwa, has extensive experience in developing, conducting and monitoring clinical trials and an excellent track record in the recruitment of patients. The Center currently works closely with the Parkinson Association of Greater Kansas City, and all of its support groups to facilitate patient recruitment. The University of Kansas Parkinson s Disease Center is willing and dedicated to adhere to a common protocol and to cooperate with other centers and NINDS in the conduct of both pilot studies and the main efficacy study.

Keywords: Parkinson s disease, chemoprevention, human therapy evaluation, nervous system disorder therapy, neuroprotectant, clinical trial, cooperative study, medical outreach /case finding, neuropharmacology, clinical research, human subject, patient oriented research

Project start date: 2006-01-20

Project end date: 2008-01-31

5U10NS044469-06 (2007): $52838


7U10NS044469-05 (2006): $29400

5U10NS044469-02 (2003): $108045

1U10NS044469-01 (2002): $108658

KU CENTER FOR NEUROPROTECTION IN PARKINSON´S DISEASE

Rajesh Pahwa
University Of Kansas Medical Center, Msn 1039, Kansas City, Ks 66160

Grant 5U10NS044469-09 from National Institute Of Neurological Disorders And Stroke

Abstract: The University of Kansas has all of the necessary components to become a Parkinson´s Disease Neuroprotection Clinical Trial Center. The University of Kansas is an established Clinical Trials Center with the necessary space to efficiently conduct clinical trials, prepare and process lab specimens and securely and confidentially maintain study medication and documentation. An experienced clinical trial team is currently in place to assure that the studies are conducted in a manner that allows for accurate, efficient and timely collection of data and provides a safe and pleasant environment for the patients. The Clinical Trial Staff have all received training and certification to conduct clinical trials from the University of Kansas Research Compliance Office and have been trained and currently follow Good Clinical Practice Guidelines to assure the safety and protection of study participants. The Principle Investigator, Dr. Rajesh Pahwa, has extensive experience in developing, conducting and monitoring clinical trials and an excellent track record in the recruitment of patients. The Center currently works closely with the Parkinson Association of Greater Kansas City, and all of its support groups to facilitate patient recruitment. The University of Kansas Parkinson´s Disease Center is willing and dedicated to adhere to a common protocol and to cooperate with other centers and NINDS in the conduct of both pilot studies and the main efficacy study

Keywords: Certification; Cities; Clinical Practice Guideline; Clinical Practice Guidelines; Clinical Trials; Clinical Trials, Monitoring; Clinical Trials, Unspecified; Conduct Clinical Trials; Confidentiality; Data; Data Collection; Disease; Disorder; Documentation; Double-Blind Method; Double-Blind Study; Double-Blinded; Double-Masked Method; Double-Masked Study; Drugs; Ensure; Environment; Idiopathic Parkinson Disease; Investigators; Kansas; Lewy Body Parkinson Disease; Medication; Monitoring Clinical Trials; NIH; National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Institutes of Health (U.S.); Paralysis Agitans; Parkinson; Parkinson Disease; Parkinson`s; Parkinson`s disease; Parkinsons disease; Participant; Patient Recruitments; Patients; Performance; Pharmaceutic Preparations; Pharmaceutical Preparations; Pilot Projects; Primary Parkinsonism; Process; Protocol; Protocols documentation; Randomized Clinical Trials; Recruitment Activity; Recruitments, Patient; Research; Research Personnel; Research Specimen; Researchers; Safety; Self-Help Groups; Specimen; Support Groups; Training; Trials, Randomized Clinical; United States National Institutes of Health; Universities; Work; clinical investigation; disease/disorder; drug/agent; experience; neuroprotection; pilot study; privacy of information; recruit; self help organization

Project start date: 2006-01-20

Project end date: 2012-11-30

Budget start date: 1-DEC-2009

Budget end date: 30-NOV-2010

PFA/PA: RFA-NS-02-010

5U10NS044469-09 (2010): $60693


Rajesh Pahwa
University Of Kansas Medical Center

Project start date: 2006-01-20

Project end date: 2012-11-30